171 related articles for article (PubMed ID: 34535011)
1. Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI.
Schultze-Florey CR; Kuhlmann L; Raha S; Barros-Martins J; Odak I; Tan L; Xiao Y; Ravens S; Hambach L; Venturini L; Stadler M; Eder M; Thol F; Heuser M; Förster R; Ganser A; Prinz I; Koenecke C
Blood Adv; 2021 Nov; 5(21):4485-4499. PubMed ID: 34535011
[TBL] [Abstract][Full Text] [Related]
2. Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse.
Odak I; Sikora R; Riemann L; Bayir LM; Beck M; Drenker M; Xiao Y; Schneider J; Dammann E; Stadler M; Eder M; Ganser A; Förster R; Koenecke C; Schultze-Florey CR
Front Immunol; 2022; 13():999163. PubMed ID: 36275657
[TBL] [Abstract][Full Text] [Related]
3. Healthy-like CD4
Schneider J; Kuhlmann L; Xiao Y; Raha S; Bernhardt G; Stadler M; Thol F; Heuser M; Eder M; Ganser A; Ravens S; Förster R; Prinz I; Koenecke C; Schultze-Florey CR
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142824
[TBL] [Abstract][Full Text] [Related]
4. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.
Claret EJ; Alyea EP; Orsini E; Pickett CC; Collins H; Wang Y; Neuberg D; Soiffer RJ; Ritz J
J Clin Invest; 1997 Aug; 100(4):855-66. PubMed ID: 9259585
[TBL] [Abstract][Full Text] [Related]
5. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
[TBL] [Abstract][Full Text] [Related]
6. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT.
Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
Ghobadi A; Choi J; Fiala MA; Fletcher T; Liu J; Eissenberg LG; Abboud C; Cashen A; Vij R; Schroeder MA; Pusic I; Stockerl-Goldstein K; Jacoby M; Uy G; DiPersio J; Westervelt P
Leuk Res; 2016 Oct; 49():1-6. PubMed ID: 27505705
[TBL] [Abstract][Full Text] [Related]
9. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
12. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
13. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism.
Mapara MY; Kim YM; Marx J; Sykes M
Transplantation; 2003 Jul; 76(2):297-305. PubMed ID: 12883182
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
Soiffer RJ; Alyea EP; Hochberg E; Wu C; Canning C; Parikh B; Zahrieh D; Webb I; Antin J; Ritz J
Biol Blood Marrow Transplant; 2002; 8(11):625-32. PubMed ID: 12463482
[TBL] [Abstract][Full Text] [Related]
15. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
[TBL] [Abstract][Full Text] [Related]
16. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
[TBL] [Abstract][Full Text] [Related]
19. Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients.
Greiner J; Götz M; Bunjes D; Hofmann S; Wais V
J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31878060
[TBL] [Abstract][Full Text] [Related]
20. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]